Key Takeaways
- • KPS Capital Partners has signed a definitive agreement to acquire MM Packaging from MM Group for €2.4bn, according to PE Hub Europe reporting on the deal.
- • Astorg has agreed to sell iGM Resins, a chemicals business it steered through a difficult period for the European chemicals sector.
- • Astorg partner Olivier Lieven argues that mid-market private equity has a 'role to play' in medtech carve-outs and take-private transactions.
- • The medtech sector is described as ripe for carve-out and take-private activity, positioning mid-cap sponsors as potential buyers of corporate divestitures.
Summary
KPS Capital Partners has signed a definitive agreement to acquire MM Packaging from MM Group for €2.4bn, according to the PE Hub Europe report. The transaction represents a sizeable carve-out of the packaging division from its parent, MM Group, and adds a sizeable industrial packaging asset to KPS's portfolio.
In a separate development, Astorg has agreed to sell iGM Resins. The report notes that Astorg steered the company through a challenging period for the European chemicals sector, a backdrop that has pressured margins and valuations across the industry.
Alongside the deal news, Astorg partner Olivier Lieven outlined his view that mid-market private equity has a 'role to play' in medtech carve-outs. The report frames the medtech sector as ripe for carve-out and take-private transactions, as corporates reassess non-core assets and sponsors look for complex separations that larger funds may not pursue. Lieven's comments position mid-cap sponsors as a credible buyer group for healthcare divestitures.
The story is part of PE Hub Europe's commentary coverage, written by Craig McGlashan, and spans healthcare, TMT and mid-market themes.
In a separate development, Astorg has agreed to sell iGM Resins. The report notes that Astorg steered the company through a challenging period for the European chemicals sector, a backdrop that has pressured margins and valuations across the industry.
Alongside the deal news, Astorg partner Olivier Lieven outlined his view that mid-market private equity has a 'role to play' in medtech carve-outs. The report frames the medtech sector as ripe for carve-out and take-private transactions, as corporates reassess non-core assets and sponsors look for complex separations that larger funds may not pursue. Lieven's comments position mid-cap sponsors as a credible buyer group for healthcare divestitures.
The story is part of PE Hub Europe's commentary coverage, written by Craig McGlashan, and spans healthcare, TMT and mid-market themes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.